This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Partial Anomalous Pulmonary Venous Connection (PAPVC)부분폐정맥결합이상

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q26.3 (Partial anomalous pulmonary venous connection) | Special Copayment Reduction: V150
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood: moderate — when only part of the pulmonary veins is abnormally connected and the left-to-right shunt volume is small, it often goes unnoticed without symptoms in childhood and is discovered incidentally in adulthood on echocardiography or chest CT, or due to reduced exercise capacity or dyspnea. If the shunt volume is large, symptoms of right ventricular overload and pulmonary hypertension may appear from childhood.
1. History17th century: anatomical description by Winslow → 1942: clinical report by Brody → 1950s: diagnosis by cardiac catheterization → since the 1990s: noninvasive diagnosis established with CT/MRI.
2. CausesAbnormality in the embryonic developmental process of the pulmonary vein–left atrium connection. Mostly sporadic. In some cases, accompanied by atrial septal defect (ASD), especially sinus venosus type ASD.
3. GeneticsMostly sporadic; no specific single-gene cause established. Some variants in cardiac development-related genes such as NKX2-5 and GATA4 have been reported. Familial occurrence is rare.
4. General epidemiologyAbout 0.4–0.7% of congenital heart disease. Prevalence of about 0.4–0.7% in autopsy studies. The type in which the right upper lobe pulmonary vein drains into the superior vena cava is the most common (about 80%).
5. PathophysiologyThe affected pulmonary vein drains into the systemic venous system (superior vena cava, inferior vena cava, right atrium, innominate vein, etc.) instead of the left atrium, forming a left-to-right shunt → right ventricular and pulmonary vascular overload.
6. SymptomsMild: asymptomatic. Moderate or greater shunt: reduced exercise capacity, dyspnea, recurrent pneumonia. Severe cases: right heart failure, symptoms of pulmonary hypertension.
7. SignsFindings of right ventricular overload: fixed splitting of the second heart sound, right ventricular impulse. Heart murmur (with accompanying ASD). ECG right axis deviation and right ventricular hypertrophy. Increased pulmonary vascular markings on chest X-ray.
8. ScreeningNo general screening. Echocardiography when a heart murmur or right ventricular hypertrophy is found; CT angiography and cardiac MRI if suspected.
9. DiagnosisEchocardiography (transthoracic, transesophageal), CT angiography (anatomical confirmation), cardiac MRI (quantification of shunt volume Qp/Qs), cardiac catheterization (measurement of pulmonary vascular resistance).
10. TreatmentSurgical correction (rerouting) when Qp/Qs ≥1.5 or right ventricular dilation is present. Simultaneous correction of accompanying ASD. Catheter-based procedures only in some selected cases.
11. PrognosisExcellent long-term prognosis with early surgical correction. Risk of progression to pulmonary hypertension if uncorrected. Arrhythmias (supraventricular) may persist after surgery.
12. PreventionPrimary prevention is difficult (sporadic). Early diagnosis and correction prevent pulmonary hypertension and right heart failure. Regular cardiac follow-up after correction.
13. ReferencesAmmash NM et al., JACC 1997; Majdalany DS et al., Congenit Heart Dis 2010, and 8 other references

1. History

Partial Anomalous Pulmonary Venous Connection (PAPVC) is a congenital heart malformation in which one or more pulmonary veins connect to the systemic venous system or the right atrium rather than the left atrium. The history of this disease begins with the development of anatomy. In the 17th century, the French anatomist Jacques-Bénigne Winslow first described an abnormal pulmonary venous connection anatomically, and subsequently in the 18th–19th centuries European pathological anatomists reported cases of various types of anomalous pulmonary venous connection. In 1942, Harold Brody of the United States described in clinical detail the type in which the right pulmonary vein drains into the inferior vena cava, and it was named 'Scimitar syndrome' because on chest X-ray the dilated right pulmonary vein takes the shape of a sword (scimitar).

In the 1950s, the spread of cardiac catheterization made it possible to measure the hemodynamic shunt in PAPVC patients, opening the era of surgical correction. In 1956, Swan et al. first reported a technique for surgically correcting the type in which the right upper lobe pulmonary vein drains into the superior vena cava (SVC). In the 1960s–1970s, various surgical techniques were developed, and methods such as patch enlargement, rerouting (baffle), and creation of a neo-right atrium were systematized.

Since the 1980s, advances in echocardiography have made noninvasive diagnosis possible, and since the 1990s, the introduction of multidetector computed tomography (MDCT) angiography and cardiac magnetic resonance imaging (CMR) has made it possible to precisely evaluate the anatomical course of the pulmonary veins, the shunt volume (Qp/Qs), and right ventricular function. In the 2000s, the feasibility of transcatheter intervention was reported in some cases, but surgery has remained the standard treatment to date. In Korea, too, PAPVC correction surgery has been systematized along with the development of pediatric and adolescent heart surgery, and awareness and management guidelines for PAPVC discovered incidentally in adults are gradually being established.

Recently, with the growth of the field of adult congenital heart disease (ACHD), research is increasing on the clinical characteristics and the timing and methods of surgery in PAPVC patients who were not diagnosed in childhood and were first identified in adulthood. In particular, the type with a right upper pulmonary vein–superior vena cava connection accompanied by sinus venosus atrial septal defect (sinus venosus ASD) is the most common type and is a major target of incidental discovery in adulthood. Quantification of shunt volume using cardiac MRI is strengthening the basis for surgical decisions, and advances in catheter-based correction methods are expected in the future.

2. Causes

The cause of PAPVC lies in the incomplete connection between the pulmonary veins and the left atrium during embryonic cardiac development. Normally, between 4 and 8 weeks of gestation, the pulmonary venous plexus connects to the developing left atrium through the primitive common pulmonary vein. In this process, as the common pulmonary vein is incorporated into the left atrial wall, the normal anatomy in which four independent pulmonary veins drain directly into the left atrium is completed.

In PAPVC, during this process one or more pulmonary veins fail to connect with the left atrium, and instead an abnormal connection with adjacent systemic venous structures (superior vena cava, inferior vena cava, right atrium, innominate vein, coronary sinus, etc.) is maintained. From an embryological perspective, this anomaly is understood to occur when regression of the connections between the embryonic systemic venous system and the pulmonary venous system is incomplete. Most PAPVC occurs sporadically, without a clear genetic cause.

PAPVC is often accompanied by sinus venosus atrial septal defect (sinus venosus ASD). When the right upper lobe pulmonary vein drains abnormally near the superior vena cava–right atrium junction, a sinus venosus ASD often forms together due to abnormal development of adjacent structures. The co-occurrence of these two anomalies is interpreted as arising from abnormal development of the same structure at the same embryological period. PAPVC may also be associated with Turner syndrome (45,X) and Scimitar syndrome (a syndrome combining right lung hypoplasia, right pulmonary vein–inferior vena cava connection, blood supply to the right lung from the aorta, etc.), in which case additional pulmonary and cardiac anomalies are present.

As with most congenital heart disease, associations with environmental factors are at the level of sporadic reports; rubella infection, diabetes, and exposure to certain drugs (valproic acid, retinoic acid derivatives, etc.) during pregnancy are known to increase the overall risk of congenital heart disease, but environmental factors specifically associated with PAPVC have not yet been established. Regarding genetic predisposition, studies have reported that variants in cardiac development-related transcription factor genes (NKX2-5, GATA4, TBX5, etc.) are associated with various congenital cardiac structural anomalies, but no gene variant specifically applicable to PAPVC has been established to date.

3. Genetics

PAPVC mostly occurs sporadically and is not classified as a genetic disease caused by a single-gene abnormality. Reports of familial PAPVC following a specific Mendelian inheritance pattern (autosomal dominant or recessive, X-linked, etc.) are very rare, and no gene has been established to date as a direct cause of PAPVC.

However, research is under way on genes that may be associated with abnormal pulmonary venous development across congenital heart disease. Variants in key transcription factors regulating cardiac development, such as NKX2-5 (NK2 homeobox 5), GATA4, TBX5, and CITED2, are associated with various congenital cardiac structural anomalies such as atrioventricular septal defect and atrial septal defect, and their possible involvement in anomalous pulmonary venous connections, including PAPVC, has been suggested. In particular, heterozygous loss-of-function variants of NKX2-5 are known to cause cardiac conduction abnormalities accompanied by atrial septal defect, and some studies have also reported an association with pulmonary venous anomalies.

In the case of Scimitar syndrome, an association with Turner syndrome (45,X) is known, and deletion of the short arm of the X chromosome is understood to increase susceptibility to abnormal cardiac development. In patients with Turner syndrome, coarctation of the aorta, bicuspid aortic valve, and pulmonary venous anomalies including PAPVC occur at high rates. Pulmonary venous anomalies have also rarely been reported in patients with 22q11.2 deletion (DiGeorge syndrome).

In congenital heart disease cohort studies using genome-wide association studies (GWAS) and next-generation sequencing (NGS), many rare variants have been reported to be associated with various cardiac developmental anomalies, including pulmonary venous anomalies, but gene variants specific to PAPVC have not yet been established. Therefore, routine genetic testing is not currently recommended clinically for PAPVC patients, but genetic counseling and comprehensive gene panel testing may be considered when there are accompanying malformations or familial occurrence is suspected. Large-scale cohort studies and genomic analyses are expected to clarify the genetic basis of PAPVC in the future.

4. General epidemiology

PAPVC is a relatively rare congenital heart malformation, reported to account for about 0.4–0.7% of all congenital heart disease. The prevalence in the general population is estimated at about 0.4–0.7% based on autopsy studies, a figure much higher than the number of clinically diagnosed patients, suggesting that many cases go undiagnosed due to an asymptomatic course. Among patients with congenital heart disease, PAPVC is reported much less often than atrial septal defect (ASD), but in reality a considerable number of simple ASDs are accompanied by PAPVC (especially in sinus venosus ASD, where PAPVC is present in about 80–90%), so prevalence may be underestimated.

According to the anatomical classification of PAPVC, the most common type is the form in which the right upper lobe pulmonary vein drains into the superior vena cava (SVC), accounting for about 80% of the total. This type is often accompanied by sinus venosus ASD and is the most common form of PAPVC discovered incidentally in adulthood. The second most common type is Scimitar syndrome, in which all or part of the right pulmonary veins drain into the inferior vena cava (IVC), often accompanied by complex malformations such as right lung hypoplasia, systemic arterial supply to the right lung (sequestration), and diaphragmatic hernia. PAPVC of the left pulmonary veins is rare, and forms draining into the innominate vein or a left superior vena cava have been reported.

Regarding sex distribution, there are reports that Scimitar syndrome is about 1.5–2 times more common in women, but there is no clear sex difference in PAPVC in general. Age distribution varies by type: cases with a large shunt become symptomatic and are diagnosed in childhood, while those with a small shunt volume are discovered incidentally in adulthood. Large-scale epidemiological studies on the prevalence of PAPVC in East Asia, including Korea, are limited, but it is estimated to be at a level similar to Western reports. Accurate domestic statistics on patients with congenital pulmonary venous anomalies registered under Special Copayment Reduction code V150 can be obtained from Health Insurance Review & Assessment Service (HIRA) data, but detailed statistics for PAPVC alone have not been published.

In epidemiological studies on the natural history of PAPVC, it has been reported that a considerable number of patients who remained asymptomatic and undiagnosed into adulthood progress after their 40s to increased right ventricular load, elevated pulmonary artery pressure, reduced exercise capacity, atrial fibrillation, etc. In particular, the risk of developing pulmonary hypertension is high in uncorrected patients with a significant shunt with Qp/Qs (pulmonary-to-systemic flow ratio) of 1.5 or more. Therefore, PAPVC should be considered in the differential diagnosis in adults presenting with right ventricular dilation, unexplained atrial fibrillation, or reduced exercise capacity.

5. Pathophysiology

The core pathophysiology of PAPVC is a left-to-right shunt that occurs as oxygenated blood flows through the anomalously connected pulmonary veins into the systemic venous system (right atrium, superior vena cava, inferior vena cava, etc.) instead of the left atrium. This shunt imposes an additional volume load on the right heart, resulting in right atrial and right ventricular dilation and increased pulmonary blood flow.

Shunt volume is determined by the number of anomalously connected pulmonary veins, the proportion of affected lung segments, the size of an accompanying atrial septal defect, and the state of pulmonary vascular resistance. When a single pulmonary vein is affected and the corresponding lung region is small (e.g., part of the right upper lobe), Qp/Qs is low at about 1.2–1.4 and may be clinically insignificant. In contrast, when all or most of the pulmonary veins of one lung drain into the systemic venous system, Qp/Qs becomes 2.0–3.0 or more and a significant right heart load develops.

Long-standing excessive pulmonary blood flow causes structural changes in the pulmonary vessels. Initially, medial hypertrophy of the pulmonary arteries occurs, followed by progression to intimal proliferation, arteriosclerotic changes, and intimal fibrosis, gradually increasing pulmonary vascular resistance. When pulmonary vascular resistance rises sufficiently, the direction of the shunt may reverse (Eisenmenger physiology), or pulmonary vascular hypertension itself may persist as an independent condition even if the shunt decreases. However, because in PAPVC only part of the total pulmonary blood flow drains into the systemic veins compared with total anomalous pulmonary venous connection (TAPVC), progression to pulmonary hypertension is relatively slow, and many patients live with mild symptoms into adulthood.

When right ventricular volume overload is prolonged, structural remodeling of the right ventricular myocardium progresses. It progresses from initial adaptive right ventricular dilation and eccentric hypertrophy to gradual decline in right ventricular systolic function, which leads to increased tricuspid regurgitation, elevated right atrial pressure, and the development of atrial fibrillation and atrial flutter. Atrial fibrillation is an important complication in adult patients with uncorrected PAPVC, and in some cases PAPVC is first diagnosed because of it. In Scimitar syndrome, the mechanism is more complex due to the addition of right lung hypoplasia and systemic arterial (aortic) blood supply to the right lung.

6. Symptoms

The clinical symptoms of PAPVC vary greatly depending on the number of anomalously connected pulmonary veins and the shunt volume, the presence and size of an accompanying atrial septal defect, the patient's age, and changes in pulmonary vascular resistance. When the shunt volume is small (Qp/Qs < 1.5), patients may remain asymptomatic for decades, and in such cases it is discovered incidentally in adulthood on echocardiography or chest CT performed for other reasons.

Symptoms in childhood: when the shunt volume is large, recurrent respiratory infections (pneumonia), tachycardia, and failure to thrive may appear. In Scimitar syndrome, reduced lung function and respiratory symptoms due to right lung hypoplasia may be prominent from the neonatal and infant period. Rarely, it presents with severe pulmonary hypertension in the neonatal period.

Symptoms in adulthood: the most common symptoms are reduced exercise capacity and dyspnea. Patients often experience a gradual decline in exercise capacity over several years and complain of becoming easily short of breath during daily activities without an obvious reason. When atrial fibrillation or atrial flutter develops, symptoms of palpitations, dyspnea, and irregular heartbeat appear. Some develop recurrent pneumonia, which is associated with blood flow stasis in the affected lung region and impaired pulmonary defense mechanisms. When pulmonary hypertension has progressed, dyspnea at rest, presyncopal symptoms, and cyanosis may appear.

Specific symptoms of Scimitar syndrome: characteristic features are reduced right lung function due to right lung hypoplasia, recurrent pneumonia and hemoptysis due to systemic arterial blood supply to the right lung (pulmonary sequestration), and right lung hyperinflation or atelectasis. The infantile form (accompanied by severe pulmonary hypertension) has a poor prognosis, while the adult form tends to be diagnosed late with relatively mild symptoms. As right heart failure progresses, lower limb edema, ascites, and generalized fatigue appear.

7. Signs

Physical signs of PAPVC vary depending on shunt volume, accompanying malformations, and pulmonary vascular resistance, and when the shunt is mild, physical examination may be normal.

Auscultation findings: when the shunt is significant (especially with an accompanying ASD), fixed splitting of the second heart sound (S2) is heard. This is a phenomenon in which pulmonary valve closure always occurs late regardless of the respiratory cycle, and it is also the typical auscultatory finding of atrial septal defect. A systolic ejection murmur (grade 2–3/6) may be heard over the pulmonary valve area, which is due to increased pulmonary artery blood flow. When tricuspid regurgitation is present, a systolic regurgitant murmur at the lower sternal border is added.

Inspection and palpation: when right ventricular overload is severe, a right ventricular heave (or parasternal lift) is palpated at the lower left sternal border. When pulmonary hypertension has progressed, the pulmonary valve closure sound becomes louder and the second heart sound is accentuated. Cyanosis appears only when the shunt is reversed due to Eisenmenger physiology. When atrial fibrillation is present, an irregular pulse and pulse deficit are observed.

Electrocardiogram findings: right axis deviation, right ventricular hypertrophy (right bundle branch block pattern or rSR' pattern), and right atrial enlargement may appear. Atrial fibrillation or atrial flutter may be recorded.

Chest X-ray findings: increased pulmonary vascular markings, right atrial and right ventricular enlargement, and pulmonary artery bulging are observed. In Scimitar syndrome, a sword (scimitar)-shaped shadow curving from the right lower lung field toward the inferior vena cava is characteristic. Reduced right lung volume due to right lung hypoplasia and rightward mediastinal shift may be present.

Echocardiography findings: right atrial and right ventricular dilation, abnormal right ventricular systolic function, increased tricuspid regurgitation velocity (estimating pulmonary hypertension), and leftward deviation of the interventricular septum (D-sign) are observed. Direct confirmation of the anomalous pulmonary venous connection is better seen on transesophageal echocardiography (TEE), but it is not fully confirmed in all cases, so CT or MRI is essential.

8. Screening

Universal screening of the general population for PAPVC is not currently performed. This is because the disease is relatively rare, an asymptomatic course is common, and the surgical benefit of early detection has not yet been established at a level that would justify universal screening. However, it is important to suspect PAPVC in certain clinical situations and perform appropriate testing.

Clinical situations raising suspicion: ① when unexplained right ventricular or right atrial dilation is observed on echocardiography, ② to check for accompanying PAPVC in patients diagnosed with atrial septal defect (especially sinus venosus ASD) (PAPVC is present in about 80–90% of sinus venosus ASD), ③ when a scimitar shadow is observed on chest X-ray (suspected Scimitar syndrome), ④ evaluation for possible congenital heart disease in adults with recurrent pneumonia, reduced exercise capacity, or unexplained atrial fibrillation, ⑤ during cardiac evaluation of patients with Turner syndrome.

Primary screening test: echocardiography (transthoracic), as the primary screening tool, evaluates right atrial and right ventricular size, right ventricular function, pulmonary artery pressure, tricuspid regurgitation velocity, and interventricular septal motion. If transthoracic echocardiography shows right ventricular dilation or increased Qp/Qs without a clear cause, evaluation of additional causes, including PAPVC, is needed. Transesophageal echocardiography (TEE) provides superior images, particularly for identifying sinus venosus ASD near the superior vena cava–right atrium junction and accompanying PAPVC.

Secondary confirmatory tests: CT angiography (MDCT) is excellent for precisely identifying the anatomical course of the pulmonary veins, the site of anomalous connection, and accompanying pulmonary anomalies (such as pulmonary sequestration in Scimitar syndrome). Cardiac MRI (CMR) is advantageous for quantitative measurement of shunt volume (Qp/Qs), evaluation of right ventricular volume and function, and follow-up without repeated radiation exposure. Radionuclide lung perfusion scanning may be used as an adjunct to evaluate blood flow distribution in the affected lung. Cardiac catheterization is used for measurement of pulmonary vascular resistance, vasoreactivity testing (oxygen and NO inhalation), and preoperative hemodynamic evaluation.

9. Diagnosis

PAPVC is confirmed through anatomical confirmation of the anomalous pulmonary venous connection and evaluation of hemodynamic severity. Various imaging techniques are used in a complementary manner.

Echocardiography: transthoracic echocardiography is a noninvasive first-line evaluation tool used to identify right atrial and right ventricular dilation and abnormal interventricular septal motion, estimate pulmonary artery systolic pressure from tricuspid regurgitation, and confirm the direction of pulmonary venous flow using color Doppler. Transesophageal echocardiography is superior for identifying anomalous pulmonary venous drainage at the right atrium–superior vena cava junction and sinus venosus ASD. However, it is often difficult to confirm the entire anatomy of PAPVC with echocardiography alone, so additional imaging is essential.

CT angiography (CTA): multidetector CT provides excellent resolution for accurate anatomical mapping (roadmapping) of the course of the pulmonary veins, the sites of anomalous drainage, and the affected lung segments. It is especially essential for surgical planning and for identifying systemic arterial supply vessels in Scimitar syndrome. Its drawbacks are radiation exposure and the use of iodinated contrast.

Cardiac MRI (CMR): the most reliable noninvasive method for quantitative measurement of shunt volume (Qp/Qs). Qp/Qs is calculated by measuring pulmonary artery and aortic blood flow with phase-contrast imaging. Right ventricular volume, ejection fraction, and myocardial mass can also be measured accurately. Because repeated follow-up is possible without radiation exposure, it is advantageous for growing children and adults requiring long-term follow-up. Contrast-enhanced CMR angiography (CE-MRA) is also used to confirm pulmonary venous anatomy.

Cardiac catheterization: the shunt site and Qp/Qs are measured by stepwise oxygen saturation measurement (oxygen saturation step-up), and pulmonary vascular resistance (PVR) is measured directly. In patients with elevated pulmonary vascular resistance, vasoreactivity (changes after oxygen and nitric oxide inhalation) is evaluated to determine operability. Currently, with advances in noninvasive imaging, cardiac catheterization solely for diagnostic purposes has decreased, and it is mainly used for measuring pulmonary vascular resistance and for interventional procedures.

10. Treatment

The key to PAPVC treatment is to perform surgical correction when there is a significant shunt (Qp/Qs ≥ 1.5 or accompanied by right ventricular dilation), rerouting the anomalous pulmonary veins to the left atrium. Treatment decisions comprehensively consider shunt volume, right ventricular size and function, pulmonary vascular resistance, accompanying malformations, and the patient's symptoms and age.

Surgical indications: ① Qp/Qs ≥ 1.5, ② presence of right ventricular volume overload (dilation), ③ presence of symptoms (reduced exercise capacity, recurrent pneumonia, atrial fibrillation), ④ preventive correction before pulmonary hypertension progresses. In asymptomatic patients with Qp/Qs < 1.5 and normal right ventricular size, the benefit of surgery is unclear, and observation or an individualized decision is recommended in this case. When pulmonary vascular resistance is severely elevated (Eisenmenger physiology), surgery is contraindicated and medical management, including pulmonary vasodilator therapy, is provided.

Surgical methods: for the most common type, a right upper lobe pulmonary vein–superior vena cava connection (with sinus venosus ASD), the Warden procedure or the intra-atrial baffle method is used. The Warden procedure reconnects the superior vena cava to the right atrial appendage and creates a patch tunnel from the superior vena cava to the left atrium that includes the pulmonary venous orifices, directing pulmonary venous blood to the left atrium. This method has a low risk of superior vena cava stenosis. In Scimitar syndrome, the right pulmonary vein is rerouted to the left atrium using a pericardial patch or an intra-atrial tunnel, sometimes combined with embolization of the systemic arterial supply vessel (sequestration vessel). An accompanying ASD is corrected simultaneously with a patch, and accompanying systemic arterial supply vessels are managed by ligation or catheter embolization.

Catheter-based procedures: in some selected patients with Scimitar syndrome, percutaneous coil embolization of the systemic arterial supply vessel is used as an adjunctive treatment. Catheter rerouting of the anomalous pulmonary vein itself is not yet standard treatment due to technical difficulties.

Drug therapy: when pulmonary hypertension is present, pulmonary vasodilators (prostacyclin derivatives, endothelin receptor antagonists, PDE-5 inhibitors) are used to improve the preoperative condition or to relieve symptoms in inoperable patients. When atrial fibrillation develops, anticoagulation and rhythm or rate control are needed.

11. Prognosis

The long-term prognosis of patients with PAPVC who are diagnosed early and receive appropriate surgical correction is generally excellent. Surgical mortality is currently reported as less than 1% at advanced cardiac centers, and most patients maintain normal or near-normal cardiopulmonary function for decades after surgery.

Long-term postoperative outcomes: right ventricular size decreases markedly within a few months after surgery, and pulmonary artery pressure also normalizes in the absence of pulmonary hypertension. Exercise capacity and quality of life improve significantly after surgical correction. The most common major postoperative complication is supraventricular arrhythmia (atrial fibrillation, atrial flutter, sick sinus syndrome). Superior vena cava or pulmonary vein stenosis may occur with some surgical techniques and is relatively rare with the Warden procedure. The risk of postoperative arrhythmia depends on age at surgery, the degree of preoperative right atrial dilation, and the type of procedure.

Natural history of uncorrected patients: when the shunt volume is small, patients may live for decades without notable symptoms, but when Qp/Qs ≥ 1.5, the risk of progression to pulmonary hypertension, right heart failure, and atrial fibrillation after the age of 40–50 is high. Because prognosis worsens markedly when it progresses to Eisenmenger physiology, correction before progression of pulmonary vascular hypertension is recommended.

Prognosis of Scimitar syndrome: the infantile-onset type (with severe pulmonary hypertension and right lung hypoplasia) has a poor prognosis, with high surgical mortality and reoperation rates. The type diagnosed in adulthood shows a relatively good prognosis after surgical correction, but reduced right lung function often persists. In the long term, additional treatment for pulmonary sequestration may be needed.

Follow-up: regular cardiac follow-up is needed even after surgical correction. Right ventricular function, pulmonary artery pressure, pulmonary vein stenosis, and arrhythmias are monitored with electrocardiography, echocardiography, Holter monitoring (arrhythmia evaluation), exercise stress testing, and cardiac MRI if necessary. Ongoing management at a specialized adult congenital heart disease (ACHD) clinic is recommended.

12. Prevention

Because PAPVC mostly occurs sporadically, primary prevention (preventing its occurrence itself) is realistically difficult. General health management before and during pregnancy that minimizes factors potentially harmful to fetal cardiac development (infections such as rubella, uncontrolled diabetes, use of teratogenic drugs) is recommended, but evidence that this directly prevents PAPVC is still lacking.

Secondary prevention — early diagnosis and correction: the most important preventive strategy is to diagnose and surgically correct PAPVC with a significant shunt before pulmonary hypertension progresses irreversibly. In children with right ventricular dilation, recurrent pneumonia, or an unexplained heart murmur, structural heart anomalies including PAPVC are actively evaluated. In adults with unexplained right ventricular dilation, atrial fibrillation, or reduced exercise capacity, confirmation of pulmonary venous anatomy by CT or cardiac MRI is considered. When sinus venosus ASD is diagnosed, the presence of accompanying PAPVC must be evaluated.

Tertiary prevention — prevention of postoperative complications: after surgical correction, regular follow-up testing is essential for early detection of arrhythmias (atrial fibrillation, sick sinus syndrome), pulmonary vein or superior vena cava stenosis, and residual shunts. In patients who develop atrial fibrillation, anticoagulation for stroke prevention is considered, and when pulmonary vascular hypertension persists, pulmonary vasodilator therapy is added. For sports activities and pregnancy, an individualized risk assessment and management plan is established in consultation with an ACHD specialist.

13. References

  1. Ammash NM, Seward JB, Warnes CA, et al. Partial anomalous pulmonary venous connection: diagnosis by transesophageal echocardiography. J Am Coll Cardiol. 1997;29(6):1351-1358. PMID: 9137238.
  2. Majdalany DS, Phillips SD, Dearani JA, et al. Isolated partial anomalous pulmonary venous connections in adults: twenty-year experience. Congenit Heart Dis. 2010;5(6):537-545. PMID: 21091919.
  3. Vida VL, Padalino MA, Boccuzzo G, et al. Scimitar syndrome: a European Congenital Heart Surgeons Association (ECHSA) multicentric study. Circulation. 2010;122(12):1159-1166. PMID: 20823388.
  4. Dillman JR, Yarram SG, Hernandez RJ. Imaging of pulmonary venous developmental anomalies. AJR Am J Roentgenol. 2009;192(5):1272-1285. PMID: 19380551.
  5. Geva T, Van Praagh S. Anomalies of the pulmonary veins. In: Allen HD, et al., eds. Moss and Adams' Heart Disease in Infants, Children, and Adolescents. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
  6. Van Praagh R, Corsini I. Cor triatriatum: pathologic anatomy and a consideration of morphogenesis based on 13 postmortem cases and a study of normal development of the pulmonary vein and atrial septum. Am Heart J. 1969;78(3):379-405. PMID: 5803892.
  7. Gustafson RA, Warden HE, Murray GF, et al. Partial anomalous pulmonary venous connection to the right side of the heart. J Thorac Cardiovasc Surg. 1989;98(5):861-868. PMID: 2509872.
  8. Trusler GA, Kazenelson G, Freedom RM, et al. Late results following repair of partial anomalous pulmonary venous connection with sinus venosus atrial septal defect. J Thorac Cardiovasc Surg. 1980;79(5):776-781. PMID: 7366498.
  9. Pourmoghadam KK, Moore JW, Khan M, et al. Transcatheter occlusion of central aortopulmonary collateral arteries in scimitar syndrome. Catheter Cardiovasc Interv. 2003;60(3):365-370. PMID: 14571482.
  10. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1028. PMID: 30121239.